Last Updated : January 7, 2020
Details
FilesGeneric Name:
insulin glargine
Project Status:
Withdrawn
Therapeutic Area:
Diabetes mellitus, Type 1 & 2
Manufacturer:
BGP PHARMA ULC
Call for patient/clinician input open:
Brand Name:
Semglee
Project Line:
Reimbursement Review
Project Number:
SE0589-000
Call for patient/clinician input closed:
Biosimilar:
Yes
Manufacturer Requested Reimbursement Criteria1:
To be listed as the preferred insulin glargine treatment for patients who have been diagnosed with type 1 or type 2 diabetes requiring long-acting insulin.
Submission Type:
Initial
Fee Schedule:
Schedule D
Indications:
Diabetes mellitus, Type 1 & 2
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | October 16, 2018 |
| Patient group input closed | December 04, 2018 |
| Clarification: - Patient input submission received from Diabetes Canada | |
| Patient input summary sent for review to patient input groups | December 12, 2018 |
| Patient group comments on input summary closed | December 19, 2018 |
| Clarification: - Patient input summary feedback received | |
| Submission received | November 14, 2018 |
| Submission accepted for review | November 29, 2018 |
| Clarification: - Submission was not accepted for review on 21 Nov 2018 | |
| Review initiated | November 30, 2018 |
| Clarification: - Voluntarily withdrawn by the manufacturer on 2019-Mar-05 | |
Files
Last Updated : January 7, 2020